Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Go back to Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases| (NASDAQ: TVTX) | Delayed: 47.07 +1.87 (4.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $45.20 | 52 Week High | $ | |||
| Open | $44.69 | 52 Week Low | $ | |||
| Day High | $47.56 | P/E | N/A | |||
| Day Low | $44.69 | EPS | $ | |||
| Volume | 901,322 | |||||
